Ryvu Therapeutics is advancing a broad pipeline by addressing emerging targets in oncology.

Our pipeline includes candidates with differentiated therapeutic mechanisms, including programs directed at kinase, synthetic lethality, immuno-oncology and immunometabolism pathways.

Clinical Projects

  • Program/ Target Name
  • Indication
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Partner
  • Anticipated
    Milestones

Discovery & Preclinical Projects

  • Program/ Target Name
  • Indication
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Partner
  • Anticipated
    Milestones

Immuno-oncology

  • A2A/B
    • Solid tumors
    • IND-enabling studies
      2020

  • STING
    • Solid tumors
    • IND-enabling studies
      2021

  • HPK1
    • Solid tumors
    • Pre-clinical candidate
      2021

Synthetic Lethality

  • SMARCA2
    • Solid tumors
  • MTAP Deletions
    • Solid tumors

Novel Targets

  • Novel Targets
    • Solid tumors

 

  • Discovery Collaborations